Statera Biopharma, Inc. (NASDAQ:STAB) (the “Company” or “Statera Biopharma”), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that, by decision dated October 26, 2022, a Nasdaq Hearings Panel granted the Company’s request for continued listing on The Nasdaq Capital Market (“Nasdaq”), subject to the Company’s satisfaction of certain interim milestones and, ultimately, the Company’s compliance with all applicable criteria for continued listing on Nasdaq, including the $1.00 bid price and $2.5 million stockholders’ equity requirements, by January 31, 2023.
Credit Suisse Maintains Neutral on Tivity Health, Raises Price Target to $31
Credit Suisse analyst Jailendra Singh maintains Tivity Health (NASDAQ:TVTY) with a Neutral and raises the price target from $29 to $31.
